Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Phase 4

Terminated

Conditions: Fatigue in Multiple Sclerosis

Interventions: Other: Physical exercise

First Posted Date: 2011-12-13

Last Posted Date: 2016-05-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 178

Registration Number: NCT01490840

Locations: 🇩🇪
Novartis Investigative Site, Unterhaching, Germany

The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: QVA149
Drug: Tiotropium
Drug: Placebo to tiotropium
Drug: Placebo to QVA149
Drug: Salbutamol/albuterol

First Posted Date: 2011-12-12

Last Posted Date: 2013-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 247

Registration Number: NCT01490125

Locations: 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: LDE225+gemcitabine

First Posted Date: 2011-12-07

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT01487785

Locations: 🇬🇧
Novartis Investigative Site, Liverpool, United Kingdom
🇺🇸
Massachusetts General Hospital Dept. of Mass General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Utah / Huntsman Cancer Institute Huntsman UT, Salt Lake City, Utah, United States

and more 1 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

Phase 1

Completed

Conditions: Dyslipidemia
Healthy Volunteers

Interventions: Drug: TAP311

First Posted Date: 2011-12-07

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 137

Registration Number: NCT01487460

Locations: 🇺🇸
Novartis Investigative Site, Miramar, Florida, United States

A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: 75 µg indacaterol maleate (PoS)
Drug: placebo to indacaterol (LB)
Drug: 37.5 µg indacaterol maleate (PoS)
Drug: 75 µg indacaterol maleate (LB)
Drug: placebo to indacaterol (PoS)

First Posted Date: 2011-12-02

Last Posted Date: 2015-04-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT01484197

Locations: 🇬🇧
Novartis Investigative Site, Machester, United Kingdom

Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: imatinib mesylate

First Posted Date: 2011-12-01

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT01483014

Locations: 🇧🇷
Novartis Investigative Site, São Paulo, SP, Brazil
🇧🇷
Novartis Investivative site, Sao Paulo, Brazil

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)

Phase 1

Completed

Conditions: Fragile X Syndrome

Interventions: Drug: AFQ056

First Posted Date: 2011-11-30

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 21

Registration Number: NCT01482143

Locations: 🇪🇸
Novartis Investigative Site, Sant Cugat, Catalunya, Spain

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors
Metastatic Breast Cancer
Metastatic Renal Cell Carcinoma

Interventions: Drug: RAD001 + BEZ235

First Posted Date: 2011-11-30

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT01482156

Locations: 🇺🇸
Washington University School of Medicine Washington University (16), Saint Louis, Missouri, United States
🇺🇸
Medical University of South Carolina SC, Charleston, South Carolina, United States
🇺🇸
Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States

and more 1 locations

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: QBX258
Drug: Placebo

First Posted Date: 2011-11-24

Last Posted Date: 2016-08-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 65

Registration Number: NCT01479595

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: AIN457 (secukinumab)
Drug: Placebo

First Posted Date: 2011-11-23

Last Posted Date: 2015-11-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT01478360

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy